Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2018

View Archived Issues

Phase I/II trial of bacteriophage therapy for the treatment of burn wounds infected by P. aeruginosa

Tryptophan metabolites contribute to multiple sclerosis risk and disease course in children

Fat receptors play role in obesity-associated pain

Triple mutant Parkinson's protein is toxic when it cannot form tetramers

ALS mutations can affect different neurons in different ways

Stronger together: combination treatment rescues CFTR folding

BMS and Compugen collaborate on studies of COM-701 plus Opdivo

SHIP2 is key in FGF signaling and necessary for the maintenance of FGF-mediated ERK activation

MEI Pharma and BeiGene to test combination of ME-401 and zanubrutinib

Phase II trial of neoadjuvant immune checkpoint blockade in high-risk resectable melanoma patients

Otsuka Pharmaceutical and Proteus Digital Health expand digital medicine collaboration

First results of elezanumab in patients with relapsing MS

Merck KGaA presents first-in-human data for evobrutinib

One-year interim analysis data presented from CHORDS study of ocrelizumab in RRMS

Novel inflammatory markers of poor clinical outcome in patients with S. aureus infection

Final phase II results of ublituximab in relapsing multiple sclerosis

Daewoong Pharmaceutical describes new BTK and/or JAK3 inhibitors

Serine-protein kinase ATM inhibitors patented by AstraZeneca

InSys and UC San Diego add third study to cannabidiol collaboration

Impetis Biosciences identifies succinate receptor 1 antagonists

Argonaut Therapeutics patents protein arginine N-methyltransferase 5 inhibitors

Gedeon Richter synthesizes GABA-B receptor positive allosteric modulators

FDA approves Xarelto to reduce risk of major CV events in coronary or peripheral artery disease

Farnesoid X receptor agonists identified at Metacrine

Iovance holds end of phase II meeting for lifileucel

Progenics plans phase II trial of 1095 for metastatic castration-resistant prostate cancer

Targovax reports DFS data from phase I/II trial of TG-01 in resected pancreatic cancer

NIH grant supports work on Feldan Shuttle to deliver CRISPR nucleases to airway epithelia

CheckMate-331 study of Opdivo in relapsed SCLC does not meet primary endpoint

Sanofi initiates first-in-human study of SAR-440234 in ALL, AML and MDS

FDA approves Yutiq for chronic noninfectious posterior segment uveitis

Australian TGA clears Peptilogics to begin phase I study of PLG-0206

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...